Development

It is anticipated that NB-00X will be appropriate as a stand alone treatment as well as a co-treatment used in conjunction with systemic anti-virals for the treatment of genital herpes.

NB-00X has demonstrated safety and efficacy in clinical trials with herpes labialis (classically associated with HSV-1) and has also shown potent activity against HSV-2 in-vitro (Fig 1). 

Fig 1:  Virucidal Activity on Herpes Simplex-2

Two doses, 0.01% and 0.05%, of NB-00X have demonstrated potent activity against HSV-2 in vitro (right).

About Genital Herpes

Genital Herpes refers to lesions of the genital area classically associated with Herpes simplex virus, type II (HSV-2).  While genital herpes cannot be cured medication can rapidly decrease the pain and discomfort associated with an outbreak and can shorten healing time as well.

Oral agents are currently being prescribed for genital herpes, including acyclovir, famciclovir, and valacyclovir.  These medications suppress the symptoms and have been shown to speed the healing and resolution of symptoms.

Recent data suggest that increasing numbers of herpes labialis infections may be due to HSV-2 and up to half of the new cases of genital herpes may be due to HSV-1.1

1. Lafferty WE (2002) The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing, Herpes, 9(2);51-55.